Vancouver-based natural drug development company Filament Health is pioneering a medical-grade ayahuasca pill. Filament Health Corp.
is obtaining FDA authorization to initiate a clinical trial for the medical form of ayahuasca, a visionary brew containing the psychedelic DMT, expecting it to occur during the first half of 2023.
- The pill is designed to give access to an authentic ayahuasca experience without disrupting your day or requiring you to travel to South America.
- According to Benjamin Lightburn, Founder and CEO of Filament Health, “different people in the same ceremony receive highly variable amounts of psychoactive substances.”
- Researchers hope the pill will give a more consistent experience with predictable effects.
- According to research, ayahuasca has been used for depression, suicidality, anxiety, trauma, grief, addiction, and substance use disorder, among others.
- The history of ayahuasca, the Amazonian psychedelic brew, goes back centuries due to its healing and visionary effects.
- The FDA is expected to rule on an application for MDMA-assisted therapy in 2023.
